
Andrew McConaghie
Senior Writer at Scrip
Senior Writer, Scrip. Pharma and healthcare updates
Articles
-
3 weeks ago |
insights.citeline.com | Andrew McConaghie
Will Pfizer Walk Away From Arvinas After PROTAC Disappointment? Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.
-
3 weeks ago |
insights.citeline.com | Andrew McConaghie
-
3 weeks ago |
insights.citeline.com | Andrew McConaghie
Merus Raises $300m After ASCO SuccessThe company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.
-
3 weeks ago |
insights.citeline.com | Andrew McConaghie
ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.
-
3 weeks ago |
insights.citeline.com | Andrew McConaghie
J&J Banks On T-Cell Engager’s Safety In Prostate Cancer The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 3K
- DMs Open
- No

RT @LBC: ❌ Ukraine started the war ❌ America provides more funding than Europe ❌ Ukraine needs immediate elections Sir Ben Wallace fact…

RT @MrBrendanCox: Please vote. https://t.co/u0Cw2aPDVD

Madrigal has just gained the first ever MASH (NASH) drug approval - but there's plenty of competition coming. $MDGL $AKRO $ETNB $VKTX @ByLizC https://t.co/FC05gvO0kB